Robert Hazlett
Stock Analyst at BTIG
(0.64)
# 3,753
Out of 4,786 analysts
25
Total ratings
34.38%
Success rate
-19.18%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.34 | +278.55% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.74 | +441.79% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.36 | +929.41% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.14 | +14,298.85% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $118.53 | -17.32% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.19 | +869.31% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $2.94 | +2,042.86% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $13.14 | +120.70% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $131.81 | -69.65% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $2.79 | +931,799.64% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $1.91 | +214.14% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.93 | +50.88% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.34
Upside: +278.55%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.74
Upside: +441.79%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.36
Upside: +929.41%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.14
Upside: +14,298.85%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $118.53
Upside: -17.32%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.19
Upside: +869.31%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $2.94
Upside: +2,042.86%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $13.14
Upside: +120.70%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $131.81
Upside: -69.65%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $2.79
Upside: +931,799.64%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.91
Upside: +214.14%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $11.93
Upside: +50.88%